Role of palliative low-molecular-weight heparin for treating venous thromboembolism in patients with advanced cancer

American Journal of Hospice and Palliative Medicine

Volumn 27, Issue 6, 2010, Pages 416-419

  Tran, Quy N H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Low molecular weight heparin; Palliative care; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

HUMAN; LUNG EMBOLISM; METHODOLOGY; NEOPLASM; PALLIATIVE THERAPY; RECURRENT DISEASE; REVIEW; RISK FACTOR; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; PALLIATIVE CARE; PULMONARY EMBOLISM; RECURRENCE; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 77955313614     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/1049909110361244     Document Type: Review

References (20)

1. Lee A. Thrombosis and cancer: the role of screening for occult cancer and recognizing the underlying biological mechanisms. Hematology Am Soc Hematol Educ Program. 2006:438-443.
2. Blom JW, Doggen CJM, Osanto S., Rosendaal FR Malignancies, prothrombotic mutations, and the risk of venous thrombosis. J AMA. 2005;293(6):715-722.
3. Heit J., Silverstein M., Mohr D., Petterson T., O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809-815.
4. Prandoni P., Lensing A., Piccioli A.,et al.Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484-3488.
5. Linkins L. Management of venous thromboembolism in patients with cancer: role of dalteparin. Vasc Health Risk Manag. 2008; 4(2):279-287.
6. Johnson M., Sproule M., Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol (R Coll Radiol). 1999;11(2):105-110.
7. Blom J., Vanderschoot J., Oostindiër M., Osanto S., Meer FVD, Rosendaal F. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. JThromb Haemost. 2006;4(3):529-535.
8. Chew H., Wun T., Harvey D., Zhou H., White R. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006; 166(4): 458-464.
9. Cronin C., Lohan D., Keane M., Roche C., Murphy J. Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. Am J Roentgenol. 2007; 189(1):162-170.
10. Lee A., Levine M., Baker R.,et al,Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153.
11. Monreal M., Zacharski L., Jiménez J., Roncales J., Vilaseca B. Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J Thromb Haemost. 2004; 2(8):1311-1315.
12. Hull R., Pineo G., Brant R.,et al,LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006;119(12):1062-1072.
13. Meyer G., Marjanovic Z., Valcke J.,et al.Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162(15):1729-1735.
14. Deitcher S., Kessler C., Merli G., Rigas J., Lyones R., Fareed J. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006;12(4):389-396.
15. Aujesky D., Smith K., Cornuz J., Roberts M. Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism. Thromb Haemost. 2005;93(3):592-599.
16. Dranitsaris G., Vincent M., Crowther M. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis. Pharmacoeconomics. 2006;24(6):593-607.
17. Noble S., Hood K., Finlay I. The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients. Palliat Med. 2007;21(6):473-476.
18. Noble S., Finlay I. Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med. 2005;19(3):197-201.
19. Soto-Cárdenas M., Pelayo-García G., Rodríguez-Camacho A., Segura-Fernández E., Mogollo-Galván A., Giron-Gonzalez J. Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice. Palliat Med. 2008;22(8):965-968.
20. Noble S., Shelley M., Coles B., Wiliams S., Wilcock A., Johnson M. Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol. 2008; 9(6):577-584.